How to Tell AVA Drugs Apart: Avapritinib vs. Avacopan

Several prescription medications go by names starting with “ava,” and a search for “ava drug” most often points to one of three: avapritinib, a targeted cancer and mast cell disease therapy sold as Ayvakit; avacopan, a steroid-sparing treatment for a rare blood vessel disease sold as Tavneos; or avanafil, a fast-acting erectile dysfunction pill sold as Stendra. These are unrelated drugs with different mechanisms, different patient populations, and different risk profiles. Because the abbreviation “AVA” also refers to the U.S. anthrax vaccine (Anthrax Vaccine Adsorbed), that sometimes surfaces in the same searches too. What follows is a practical walkthrough of each.

Avapritinib and What It Treats

Avapritinib is a targeted therapy that blocks abnormal forms of two proteins, KIT and PDGFRA, which can drive certain cancers and mast cell diseases. It earned its first FDA approval for a specific subset of gastrointestinal stromal tumors (GIST) that carry a PDGFRA D842V mutation, a genetic change that makes these tumors resistant to older drugs like imatinib. In lab models, all mutations at the 842 position of PDGFRA proved sensitive to avapritinib, regardless of which specific amino acid substitution was present.¹ In the United States, avapritinib is FDA-approved as a first-line treatment for all PDGFRA exon 18-mutant GIST cases, though outside the U.S. it is generally available only for the D842V-specific mutation.

Avapritinib also has a separate approval for two forms of systemic mastocytosis, a condition in which the body produces too many mast cells. In advanced systemic mastocytosis, four-year follow-up of the PATHFINDER trial showed a confirmed overall response rate of about 73%, with roughly 30% of patients achieving complete remission or complete remission with partial blood count recovery. Around 88% of patients saw their bone marrow mast cell counts drop by half or more, and about 74% had their bone marrow mast cell clumps clear entirely.²

For indolent systemic mastocytosis, which is a milder but still burdensome form of the disease, a placebo-controlled trial found that avapritinib cut symptom scores by about 15.6 points over 24 weeks compared with roughly 9 points in the placebo group. More than half of the patients on the drug achieved at least a 50% drop in serum tryptase, a blood marker of mast cell activity, while nobody in the placebo group did.³ Longer-term data through about three years showed that symptom improvement held up, with patients reporting a durable average drop of around 19 points on the symptom score.⁴

Avapritinib Side Effects Worth Knowing About

The side effect that gets the most attention with avapritinib is its effect on the brain. In GIST patients treated at the 300 mg dose, about 40% experienced some degree of cognitive effects, mostly mild memory issues. That rate climbed to about 50% at the higher 400 mg dose and was particularly common in patients aged 65 and older, where roughly half experienced cognitive symptoms even at the lower dose.⁵ The European Medicines Agency’s assessment noted that most cognitive effects were mild memory problems, but rarer events included severe encephalopathy and intracranial or gastrointestinal bleeding.⁶

A postmarketing analysis of FDA adverse event reports confirmed a statistically significant link between avapritinib and neuropsychiatric side effects overall, with gender and age potentially influencing how severe those effects become.⁷ Intracranial bleeding occurred in about 2.4% of patients starting at the 300 mg dose in the GIST setting.⁸ Because of these risks, doctors monitor patients closely and often adjust doses downward rather than discontinue the drug entirely.

When Avapritinib Stops Working

Like many targeted cancer drugs, avapritinib can lose effectiveness when tumors develop new mutations. In patients with PDGFRA-driven GIST who progressed on avapritinib, researchers found secondary mutations in PDGFRA exons 13, 14, and 15 that physically interfere with the drug’s ability to bind its target. Several of these mutations appeared in multiple patients, marking them as recurring resistance mechanisms rather than one-off flukes.⁹ Understanding these resistance pathways matters because it shapes which drugs might work next when avapritinib fails.

Separately, lab research has shown that avapritinib can interfere with certain drug-resistance pumps that cancer cells use to expel chemotherapy drugs. At concentrations low enough not to be toxic on their own, avapritinib restored the sensitivity of multidrug-resistant cancer cells to standard chemotherapy agents by blocking the transport proteins ABCB1 and ABCG2.¹⁰ This is still preclinical work, but it hints at a potential future role for avapritinib in combination regimens beyond its current approved uses.

Early Signals in Pediatric Patients

Avapritinib’s approvals are currently for adults, but early-stage reports suggest potential use in children. A small case series looked at six pediatric patients with KIT-mutant acute myeloid leukemia who received avapritinib after stem cell transplantation. Neutropenia was the most common side effect, occurring in all four patients who experienced adverse events. Two patients who took avapritinib as preventive therapy after transplant achieved complete remission with no detectable residual disease, and one patient whose leukemia markers reappeared after transplant saw those markers become undetectable after two months on avapritinib alone.¹¹ These are very preliminary numbers from a handful of patients, but they suggest avapritinib could eventually broaden beyond its current niche.

Avacopan for Blood Vessel Inflammation

Avacopan (brand name Tavneos) treats a completely different condition: ANCA-associated vasculitis, a rare autoimmune disease where the immune system attacks small blood vessels, often damaging the kidneys and lungs. The standard treatment has long relied on high-dose steroids alongside immunosuppressive drugs, but steroids carry their own burden of side effects, from bone thinning to diabetes to infections. Avacopan works by blocking the receptor for complement component C5a, a molecule that fuels the inflammatory attack on blood vessels.

The landmark ADVOCATE trial compared avacopan to a standard prednisone taper in 330 patients, all of whom also received either rituximab or cyclophosphamide. At 26 weeks, about 72% of avacopan patients and about 70% of prednisone patients achieved disease remission, meeting the bar for noninferiority. At one year, the gap widened: roughly 66% of the avacopan group maintained sustained remission versus about 55% on prednisone, a difference that reached statistical significance for superiority.¹² A 2026 readjudication of the trial’s endpoint by independent reviewers produced slightly lower numbers for both groups but preserved the same overall pattern: similar short-term remission rates and a trend favoring avacopan for sustained remission, alongside meaningful reductions in steroid exposure.¹³

The Steroid-Sparing and Kidney Benefits of Avacopan

For many vasculitis patients, the real appeal of avacopan is getting off steroids. In a subgroup analysis of ADVOCATE patients who received cyclophosphamide alongside avacopan, total steroid exposure over a year dropped by nearly two-thirds compared to the prednisone taper group, and a toxicity index measuring steroid-related side effects was meaningfully lower.¹⁴ That kind of reduction translates to fewer steroid-related complications over months and years of treatment.

Kidney protection has also emerged as a consistent advantage. Among ADVOCATE patients with kidney involvement, those on avacopan saw an average improvement of about 9.5 points in their estimated kidney filtration rate at one year, compared to about 6.4 points in the prednisone group. In patients who started with severely impaired kidney function, the gap was even wider.¹⁵ A systematic review of real-world data broadly supported these findings, with case series and smaller studies showing favorable kidney outcomes when avacopan was used in patients with advanced kidney damage.¹⁶ Proteinuria and blood in the urine also declined faster in the avacopan group, with early improvements visible within weeks of starting treatment.

What Avacopan Costs

Avacopan is expensive, and its cost-effectiveness depends heavily on where you live and how the health system values steroid-related complications. A Chinese economic analysis found avacopan cost-effective at a willingness-to-pay threshold tied to the country’s GDP per capita, primarily because it improved quality-adjusted life years and reduced kidney failure.¹⁷ A Spanish analysis reached a higher cost-per-QALY figure but still found avacopan favorable, largely because fewer patients progressed to end-stage kidney disease, which is enormously expensive to manage with dialysis.¹⁸ For individual patients, the sticker price can be a barrier. In the United States, avacopan typically runs in the range of tens of thousands of dollars per year, and insurance coverage varies. Patient assistance programs from the manufacturer exist but don’t cover everyone.

Avanafil for Erectile Dysfunction

Avanafil (brand name Stendra) is the newest of the four major PDE5 inhibitors used to treat erectile dysfunction, joining sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). Its main selling point is speed. In lab testing, avanafil reached peak activity in about 10 minutes, compared to about 30 minutes for sildenafil.¹⁹ In practice, this translates to a recommended dosing window as short as 15 minutes before sexual activity, though many men find results in clinical trials cluster closer to the 15-to-30-minute window.

What sets avanafil apart biochemically is its selectivity. All PDE5 inhibitors carry some risk of side effects caused by unintentionally blocking related enzymes in other tissues. Avanafil showed roughly 121-fold selectivity against PDE6, the enzyme in the retina responsible for the color vision changes some men experience with sildenafil, which only manages about 16- to 21-fold selectivity there. Avanafil also showed better than 10,000-fold selectivity against PDE1 and better than 19,000-fold selectivity against PDE11, the enzyme linked to back pain and muscle aches sometimes seen with tadalafil.²⁰ In plain terms, this enhanced selectivity means avanafil is less likely to cause visual disturbances or muscle-related side effects than some of the older options.

Avanafil’s half-life is in the same range as sildenafil and vardenafil, meaning its effects last several hours but not as long as tadalafil’s 36-hour window.²¹ That makes it more of a “take it when you need it” medication. For men who prefer spontaneity over a longer duration, or who have had trouble with side effects from other PDE5 inhibitors, avanafil fills a specific niche. It is available in 50 mg, 100 mg, and 200 mg tablets, with most men starting at 100 mg.

AVA, the Anthrax Vaccine

The acronym AVA stands for Anthrax Vaccine Adsorbed, marketed as BioThrax. It is the only FDA-licensed anthrax vaccine for humans in the United States and is used primarily by military personnel and certain laboratory workers. The vaccine works by generating immune responses against protective antigen (PA), a protein that the anthrax bacterium uses to deliver its toxins into human cells. Research has shown that an effective PA-based vaccine prevents anthrax not by neutralizing toxin molecule by molecule but by stopping the bacteria from establishing a body-wide infection in the first place.²²

The standard vaccination schedule originally required six doses over 18 months, all given subcutaneously, followed by annual boosters. A large randomized trial found that switching to intramuscular injection produced an equivalent immune response while cutting injection-site pain by about half.²³ This led to a revised schedule that reduced the priming series and switched to the intramuscular route, making the vaccine easier to tolerate. In a post-exposure scenario, combining the vaccine with antibiotics significantly improved survival in animal studies compared to antibiotics alone, supporting its role as an emergency countermeasure after a potential anthrax exposure.²⁴

The immune response to AVA involves both antibodies and cell-mediated immunity, with studies in humans showing a mixed immune profile that favors antibody production but also engages cellular defenses and generates memory B cells that persist for years.²⁵ Researchers have also explored adding immune-boosting molecules to the vaccine to potentially allow fewer doses while achieving the same level of protection, with early human trials showing that certain adjuvants can markedly increase antibody levels.²⁶

How to Tell These Drugs Apart

If you have encountered the term “ava drug” and are not sure which medication is relevant to you, the context usually makes it obvious. Avapritinib is discussed in the context of GIST, mastocytosis, or mast cell disease, and its brand name Ayvakit may appear on the prescription label. Avacopan comes up in the context of vasculitis, kidney inflammation, or steroid tapering, and its brand name Tavneos is the giveaway. Avanafil is almost always discussed alongside other erectile dysfunction medications, and its brand name Stendra is widely advertised. AVA, the anthrax vaccine, appears exclusively in military, biodefense, or occupational health contexts.

These medications are not interchangeable, and confusion between them could have serious consequences. If a doctor or pharmacist mentions an “ava” drug and the context is unclear, asking for the full generic name and the brand name removes any ambiguity. Each drug has a distinct dosing schedule, a distinct set of side effects, and a distinct population that benefits from it. The only thing they share is a few opening letters.